Ruvonoflast aims to address the restricted blood flow and numbness associated with plaque buildup in arteries. According to the company, the drug candidate has completed five human clinical trials, demonstrating a favorable safety profile and the ability to achieve broad tissue distribution, including reach into the central nervous system. Rezera prioritized this indication due to the substantial unmet medical need within a large patient population suffering from the condition.

While the filing marks a significant step toward public markets, the company has not yet disclosed the anticipated size of the offering or a projected price range for its shares. Investors are awaiting further details on the valuation and the specific timeline for the Nasdaq debut.